Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

Financial Performance - Taysha Gene Therapies reported a quarterly loss of $0.08 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.10 per share a year ago [1] - The company posted revenues of $2.3 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 9.62%, but down from $3.41 million year-over-year [2] - Over the last four quarters, Taysha Gene Therapies has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2][1] Stock Performance - Taysha Gene Therapies shares have increased approximately 37% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $1.93 million, and for the current fiscal year, it is -$0.34 on revenues of $7.96 million [7] - The estimate revisions trend for Taysha Gene Therapies is mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Generic Drugs industry, to which Taysha Gene Therapies belongs, is currently ranked in the bottom 24% of over 250 Zacks industries, indicating potential challenges ahead [8]